According to the analyst's market research, the sales value of Metformin in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the overall medical diagnosis and treatment services, the sales value of Metformin in the Chinese market fell to CNY707 million in 2020, a year-on-year decline of 4.19%. The CAGR of Metformin sales value in the Chinese market from 2016 to 2020 is 7.01%.
The analyst expects that with the relief of COVID-19, the sales value of Metformin in the Chinese market will have a restorative growth from 2021 to 2025. In addition, the number of diabetic patients in China ranks first in the world. The total prevalence rate of diabetes in adults is 12.8%. Type II diabetes accounts for 90% of diabetic patients, and the number of patients is huge. At the same time, as the population ageing in China is becoming increasingly severe, the number of patients and the prevalence rate are also increasing year by year. Therefore, the sales volume and sales value of Metformin for the treatment of type 2 diabetes have an increasing trend. In addition, compared with similar drugs, Metformin not only has the effect of lowering blood sugar, but also may have the effect of weight loss and treatment of hyperinsulinemia, and it can be effective for patients with poor efficacy of certain sulfonylureas. Based on these advantages, it is expected that the sales value of Metformin in the Chinese market will increase from 2021 to 2025.
Topics Covered:
- The impact of COVID-19 on China's Metformin market
- Sales value of China's Metformin 2016-2020
- Competitive landscape of China's Metformin market
- Prices of Metformin in China
- Prices of Metformin in China by regions and manufacturers
- Analysis on factors affecting the development of China's Metformin market
- Prospect of China's Metformin market from 2021 to 2025
Table of Contents
Samples
LOADING...
Companies Mentioned
- Sino-American Shanghai Squibb Pharmaceutical Ltd. (GLUCOPHAGE)
- Merck Sante SA (GLUCOPHAGE)
- Chongqing Kangker Pharmaceutical Co., Ltd. (Dulening)
- Beijing Shengyong Pharmaceutical Co., Ltd. (Junlida)
- Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.
Methodology
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 50 |
Published | July 2021 |
Forecast Period | 2016 - 2025 |
Estimated Market Value ( CNY | CNY 539.32 Million |
Forecasted Market Value ( CNY | CNY 1302.9 Million |
Compound Annual Growth Rate | 10.2% |
Regions Covered | China |
No. of Companies Mentioned | 5 |